Paper Details

  1. Home
  2. Paper Details

[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol].

Author: LachenmayerL, ReichmannH

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study recommends using dopamine agonists early in Parkinson's disease treatment, particularly for younger and middle-aged patients with idiopathic Parkinson's syndrome. A 5-year study comparing L-dopa with ropinirole, a dopamine agonist, found that ropinirole was as effective as L-dopa but with a significantly lower risk of dyskinesias (5% vs. 36%). This suggests that dopamine agonists may be a better long-term option, especially for patients who might experience dyskinesias sooner with L-dopa.
Paper Details　
Original Abstract of the Article :
Psychiatric symptoms and motor fluctuations are frequently occurring late sequelae of long-term therapy with L-dopa. Up to 80% of patients on L-dopa therapy suffer from disturbing dyskinesias, with onset during the first few years after beginning treatment. In particular, younger and middle-aged pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s001150050701

データ提供：米国国立医学図書館（NLM）

Ropinirole: A Potential Game-Changer for Parkinson's Disease Treatment

Parkinson's disease, a neurological disorder that affects movement, poses a significant challenge for patients and healthcare professionals. This study explores the potential of ropinirole, a dopamine agonist, as an effective treatment for Parkinson's disease. The study conducted a double-blind comparison of ropinirole and L-dopa, a traditional treatment for Parkinson's, over a 5-year period. The results show that ropinirole was equally effective in managing Parkinson's symptoms, but with a significantly lower incidence of dyskinesias, involuntary movements that can be a troublesome side effect of L-dopa therapy.

Ropinirole: A Potential for Reducing Dyskinesias in Parkinson's Disease

The study found that only 5% of patients treated with ropinirole developed dyskinesias, compared to 36% of those treated with L-dopa. This is a significant difference, suggesting that ropinirole might be a more tolerable treatment option for some patients. The study also found that at least one-third of the patients treated with ropinirole could be managed with the dopamine agonist alone for the entire 5-year period. These findings suggest that ropinirole could potentially delay or even eliminate the need for L-dopa therapy in some individuals with Parkinson's disease, which could help prevent the development of dyskinesias.

Implications for Parkinson's Disease Management

This study offers a glimmer of hope for patients with Parkinson's disease, suggesting a potential alternative treatment option that may reduce the risk of dyskinesias. The results emphasize the importance of considering dopamine agonists like ropinirole as an early treatment option for Parkinson's disease, especially for younger patients who may be more susceptible to dyskinesias.

Dr.Camel's Conclusion

This research is like finding a cool oasis in a hot desert for those dealing with Parkinson's disease. It suggests that ropinirole might offer a more comfortable path for managing symptoms, potentially delaying or even eliminating the need for L-dopa therapy.

Date :
  1. Date Completed 2001-03-01
  2. Date Revised 2019-10-25
Further Info :

Pubmed ID

11139984

DOI: Digital Object Identifier

10.1007/s001150050701

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.